# A Trial of Metformin in Individuals With Fragile X Syndrome (Met)

> **NCT03862950** · PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 125 (actual)

## Conditions studied

- Fragile X Syndrome
- Fragile X Mental Retardation Syndrome
- Mental Retardation, X-Linked
- Genetic Diseases, X-Linked
- Trinucleotide Repeat Expansion
- Fra(X) Syndrome
- Intellectual Disability
- FXS
- Neurobehavioral Manifestations
- Sex Chromosome Disorders

## Interventions

- **DRUG:** Placebo Medication
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03862950
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2025-12-16
- **Final completion:** 2025-12-16
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862950, "A Trial of Metformin in Individuals With Fragile X Syndrome (Met)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03862950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*